Developer docs
API playgroundTry for free, no card

Search company profiles

SCA Pharmaceuticals

Full company profile

uuid000ko4t

Namestring
SCA Pharmaceuticals
Legal namestring
SCA Pharmaceuticals, LLC
Websiteurl
scapharma.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

SCA Pharmaceuticals, LLC (dba SCA Pharma) is an FDA 503B outsourcing facility specializing in sterile compounding of injectable pharmaceuticals for hospital and healthcare facility pharmacies. Founded in Little Rock, Arkansas and operating as a privately held company since 2009, SCA Pharma produces sterile admixtures and pre-filled syringes across approximately 200 National Drug Codes in 15 product categories spanning critical care, labor and delivery, anesthesia, and pain management. The company operates two state-of-the-art cGMP-compliant facilities—a 90,000 sq. ft. site in Windsor, Connecticut and a facility in Little Rock, Arkansas—totaling 120,000 sq. ft., and is licensed to operate in 49 states plus Washington, D.C.

Core operations run on Current Good Manufacturing Practice standards under 21 CFR Part 211, FDA 503B GMP guidance, and ICH Q9(R1)/Q10 quality risk and pharmaceutical quality system frameworks. Technology and quality differentiation come from rapid microbiological testing platforms (Celsis ATP bioluminescence validated per USP <1223>, Charles River Endosafe-MCS, Rapid Micro Biosystems Growth Direct), advanced chromatography (HPLC/UPLC), subvisible particulate testing, RFID tagging via Kit Check (the company is the first 503B to apply this across all products and is a DoseID consortium member), and a MasterControl electronic QMS covering training, deviation, CAPA, change control, and supplier audits. An Independent Quality Unit with 90+ quality professionals and 20 licensed pharmacists reports to the CEO. Extended Beyond Use Dating on 69+ products (up to 180 days) reduces hospital drug waste.

SCA Pharma generates revenue through B2B transaction-based sales of compounded sterile products. Go-to-market combines dedicated inside and outside sales teams, a proprietary customer portal (partner.scapharma.com) with recurring-order and new-product-request functionality, a multi-year Vizient GPO agreement reaching over 60% of U.S. healthcare organizations, and since 2025 a Medigi digital procurement platform integration including controlled substances. Distribution is supported by ~5,800 shipments per month nationwide. The company is owned by The Vistria Group and Excellere Partners following a January 2021 acquisition from Enhanced Healthcare Partners.

Short descriptiontext

SCA Pharmaceuticals is an FDA 503B outsourcing facility producing sterile admixtures and pre-filled syringes across ~200 NDCs for hospital and healthcare facility pharmacies in the United States, operating two cGMP facilities in Little Rock, AR and Windsor, CT.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLittle Rock, United States
HQ citystring
Little Rock
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Sterile compounding services, 503B outsourcing, Pre-filled syringes, Hospital pharmacy supply, Sterile admixture manufacturing
Industry3 codes
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Sterile Compounded Pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Sterile Compounding Product Sales
TypeTransaction Fee
Description

Sale of FDA 503B compliant sterile admixtures and pre-filled syringes to hospital and healthcare facility pharmacies. Products include critical care, labor and delivery, anesthesia, pain management medications, and drug-shortage medications. Revenue generated through direct sales, online portal orders, and channel partner platforms.

scapharma.com
2Distribution Platform Sales
TypeTransaction Fee
Description

Products sold through Medigi digital procurement platform and other purchasing platforms as alternate distribution channels.

scapharma.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SCA Pharmaceuticals is an FDA-registered 503B outsourcing facility that performs cGMP-compliant sterile compounding of ready-to-use medications for hospital and healthcare facility pharmacies. The company manufactures pre-filled syringes, sterile IV admixtures, and other injectable preparations across approximately 200 product NDCs spanning 15 therapeutic categories. Operations run from two state-of-the-art facilities totaling 120,000 sq. ft. in Little Rock, AR and Windsor, CT, with the company licensed in 49 states and Washington D.C.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Buy & Ship Now orders ship within next business day for orders placed from available inventory
+3 more records
Product overview1 text field

SCA Pharma is a 503B sterile compounding outsourcing facility providing hospital and healthcare facility pharmacies with sterile admixture services and pre-filled syringes. The company operates two state-of-the-art facilities (Little Rock, AR and Windsor, CT) with a portfolio of approximately 200 product NDCs across 15 product categories including critical care, labor and delivery, anesthesia, and pain management medications. Key products include Hydromorphone HCl (various concentrations in IV bags), Sugammadex (pre-filled syringes with up to 120-day BUD), Ketamine HCl, and other analgesics, cardiovascular agents, and anesthetics. The company offers a customer portal for ordering and Buy and Ship Now rapid delivery service.

Product and service9 records
1Sterile Admixture Services
CategorySterile Compounding
Description

cGMP-compliant sterile compounding and admixture manufacturing service for hospital and healthcare facility pharmacies, producing ready-to-use injectable preparations.

2Pre-filled Syringes
CategorySterile Injectables
Description

Ready-to-administer pre-filled syringes manufactured under cGMP conditions for hospital use, available across multiple therapeutic categories.

3Hydromorphone HCl
CategoryPain Management
Description

Sterile compounded Hydromorphone HCl injectable preparation manufactured by SCA Pharma as part of its 503B product catalog.

4Sugammadex
CategoryAnesthesia
Description

Sterile compounded Sugammadex injectable preparation manufactured by SCA Pharma for neuromuscular blockade reversal in hospital settings.

5Ketamine HCl
CategoryAnesthesia
Description

Sterile compounded Ketamine HCl injectable preparation produced for hospital and surgical use.

6Potassium Phosphate
CategoryElectrolytes
Description

Sterile compounded Potassium Phosphate injectable preparation manufactured for electrolyte replacement in hospital pharmacy settings.

7Customer Portal Ordering Service
CategoryOrdering and Fulfillment
Description

Online ordering and account management platform allowing providers to browse the full SCA catalog, place orders, pay invoices, and track shipments in real time.

8Buy and Ship Now Service
CategoryOrdering and Fulfillment
Description

Expedited order processing and direct shipment service offered through the SCA customer portal for urgent hospital pharmacy needs.

9Pharmacy Reliability Program
CategorySupply Continuity
Description

SCA's Pharmacy Reliability Program offers hospital pharmacies a stable, contracted supply of ready-to-use compounded sterile preparations, including extended BUD dating on 69+ products to reduce drug waste.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-26
Description

Strategic partnership expansion providing direct access to controlled substances (CII products) through Medigi platform. Platform integration enables existing Medigi users to seamlessly add SCA Pharma products without retraining on new software systems.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-10
Description

SCA Pharma expanded distribution of core pharmaceutical products to Medigi digital procurement platform, providing healthcare facilities with additional purchasing options. Medigi integration enables streamlined ordering through existing hospital procurement systems with full product portfolio access including critical CII products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-11-01
Description

Multi-year agreement awarded by Vizient for SCA Pharma's full range of 503B ready-to-use products. Vizient serves over 60% of U.S. health care organizations. Third-party 503B/cGMP assessment confirmed SCA facilities produce high-quality, safe, and efficacious products in compliance with 503B requirements.

4Kit Check
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-09-10
Description

First 503B company to use Kit Check's embedded RFID tag on all products for automated medication tracking and safety verification. Enables medication intelligence through radio-frequency identification technology.

scapharma.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-04-16
Description

Partnership during COVID-19 to compound and distribute over 2,500 containers of alcohol-based hand sanitizer at no cost to first responders and front-line healthcare workers in Connecticut.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

QuVa is a 503B outsourcing facility providing sterile compounded admixtures and ready-to-use presentations to U.S. hospital pharmacies — the closest direct competitor to SCA in the same regulatory and product category.

TypeDirect peer
Description

Leiters is a FDA-registered 503B outsourcing facility producing sterile admixtures, pre-filled syringes, and ophthalmic preparations for hospital and clinical customers — directly comparable in product format and end-market to SCA Pharma.

TypeBroad incumbent
Description

B. Braun's Central Admixture Pharmacy Services (CAPS) is an established 503B sterile compounder serving hospitals nationally — competes directly with SCA but as part of a much larger medical products company.

TypeDirect peer
Description

Olympia is a 503B-registered sterile outsourcing facility producing compounded sterile preparations for hospitals — comparable in regulatory standing, customer base, and product format to SCA.

TypeDirect peer
Description

Avella operates a 503B outsourcing facility producing sterile admixtures and prefilled syringes for hospital customers — overlaps directly with SCA's core product portfolio and hospital-segment focus.

TypeBroad incumbent
Description

Fagron is a global leader in pharmaceutical compounding offering APIs, excipients, and compounding services — a broader industry incumbent with overlapping reach into sterile and non-sterile compounding adjacent to SCA's domain.

7Stokes Healthcare
TypeEmerging player
Description

Stokes operates a 503B outsourcing facility focused on sterile preparations for hospitals and specialty pharmacies — an emerging player with meaningful product overlap but smaller national reach than SCA.

TypeEmerging player
Description

Wells Pharma operates a 503B-registered sterile compounding outsourcing facility with hospital customers — emerging peer with comparable regulatory profile and product set but more limited national penetration than SCA.

TypeBroad incumbent
Description

Pfizer CentreOne provides contract sterile manufacturing and injectable supply to hospital and 503B-adjacent customers — a much larger incumbent with overlapping capacity and quality standards relevant to SCA's hospital customer base.

TypeBroad incumbent
Description

Curia is a contract development and manufacturing organization with sterile injectable fill-finish capabilities serving pharma and hospital customers — comparable in regulatory depth and sterile manufacturing scale to SCA though broader in scope.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SCA Pharmaceuticals

Sterile Compounded Pharmaceuticalsscapharma.com

SCA Pharmaceuticals is an FDA 503B outsourcing facility producing sterile admixtures and pre-filled syringes across ~200 NDCs for hospital and healthcare facility pharmacies in the United States, operating two cGMP facilities in Little Rock, AR and Windsor, CT.

What SCA Pharmaceuticals does

SCA Pharmaceuticals, LLC (dba SCA Pharma) is an FDA 503B outsourcing facility specializing in sterile compounding of injectable pharmaceuticals for hospital and healthcare facility pharmacies. Founded in Little Rock, Arkansas and operating as a privately held company since 2009, SCA Pharma produces sterile admixtures and pre-filled syringes across approximately 200 National Drug Codes in 15 product categories spanning critical care, labor and delivery, anesthesia, and pain management. The company operates two state-of-the-art cGMP-compliant facilities—a 90,000 sq. ft. site in Windsor, Connecticut and a facility in Little Rock, Arkansas—totaling 120,000 sq. ft., and is licensed to operate in 49 states plus Washington, D.C.

Core operations run on Current Good Manufacturing Practice standards under 21 CFR Part 211, FDA 503B GMP guidance, and ICH Q9(R1)/Q10 quality risk and pharmaceutical quality system frameworks. Technology and quality differentiation come from rapid microbiological testing platforms (Celsis ATP bioluminescence validated per USP <1223>, Charles River Endosafe-MCS, Rapid Micro Biosystems Growth Direct), advanced chromatography (HPLC/UPLC), subvisible particulate testing, RFID tagging via Kit Check (the company is the first 503B to apply this across all products and is a DoseID consortium member), and a MasterControl electronic QMS covering training, deviation, CAPA, change control, and supplier audits. An Independent Quality Unit with 90+ quality professionals and 20 licensed pharmacists reports to the CEO. Extended Beyond Use Dating on 69+ products (up to 180 days) reduces hospital drug waste.

SCA Pharma generates revenue through B2B transaction-based sales of compounded sterile products. Go-to-market combines dedicated inside and outside sales teams, a proprietary customer portal (partner.scapharma.com) with recurring-order and new-product-request functionality, a multi-year Vizient GPO agreement reaching over 60% of U.S. healthcare organizations, and since 2025 a Medigi digital procurement platform integration including controlled substances. Distribution is supported by ~5,800 shipments per month nationwide. The company is owned by The Vistria Group and Excellere Partners following a January 2021 acquisition from Enhanced Healthcare Partners.

SCA Pharmaceuticals firmographics

Firmographics
Name
SCA Pharmaceuticals
Legal name
SCA Pharmaceuticals, LLC
Website
https://scapharma.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
251–500 employees
Short description
SCA Pharmaceuticals is an FDA 503B outsourcing facility producing sterile admixtures and pre-filled syringes across ~200 NDCs for hospital and healthcare facility pharmacies in the United States, operating two cGMP facilities in Little Rock, AR and Windsor, CT.
Ownership category
akta.pro rank

SCA Pharmaceuticals industry classification

Industry
Product category
Sterile Compounded Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Sterile compounding services
  • 503B outsourcing
  • Pre-filled syringes
  • Hospital pharmacy supply
  • Sterile admixture manufacturing

Where SCA Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Little Rock
HQ country
United States
HQ region
North America

Offices3 records

Markets served

SCA Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Sterile Compounding Product Sales: Sale of FDA 503B compliant sterile admixtures and pre-filled syringes to hospital and healthcare facility pharmacies. Products include critical care, labor and delivery, anesthesia, pain management medications, and drug-shortage medications. Revenue generated through direct sales, online portal orders, and channel partner platforms.
  2. Distribution Platform Sales: Products sold through Medigi digital procurement platform and other purchasing platforms as alternate distribution channels.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

SCA Pharmaceuticals product offering

Product offering

Core offering

SCA Pharmaceuticals is an FDA-registered 503B outsourcing facility that performs cGMP-compliant sterile compounding of ready-to-use medications for hospital and healthcare facility pharmacies. The company manufactures pre-filled syringes, sterile IV admixtures, and other injectable preparations across approximately 200 product NDCs spanning 15 therapeutic categories. Operations run from two state-of-the-art facilities totaling 120,000 sq. ft. in Little Rock, AR and Windsor, CT, with the company licensed in 49 states and Washington D.C.

Product overview

SCA Pharma is a 503B sterile compounding outsourcing facility providing hospital and healthcare facility pharmacies with sterile admixture services and pre-filled syringes. The company operates two state-of-the-art facilities (Little Rock, AR and Windsor, CT) with a portfolio of approximately 200 product NDCs across 15 product categories including critical care, labor and delivery, anesthesia, and pain management medications. Key products include Hydromorphone HCl (various concentrations in IV bags), Sugammadex (pre-filled syringes with up to 120-day BUD), Ketamine HCl, and other analgesics, cardiovascular agents, and anesthetics. The company offers a customer portal for ordering and Buy and Ship Now rapid delivery service.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sterile Admixture Services cGMP-compliant sterile compounding and admixture manufacturing service for hospital and healthcare facility pharmacies, producing ready-to-use injectable preparations.
  • Pre-filled Syringes Ready-to-administer pre-filled syringes manufactured under cGMP conditions for hospital use, available across multiple therapeutic categories.
  • Hydromorphone HCl Sterile compounded Hydromorphone HCl injectable preparation manufactured by SCA Pharma as part of its 503B product catalog.
  • Sugammadex Sterile compounded Sugammadex injectable preparation manufactured by SCA Pharma for neuromuscular blockade reversal in hospital settings.
  • Ketamine HCl Sterile compounded Ketamine HCl injectable preparation produced for hospital and surgical use.
  • Potassium Phosphate Sterile compounded Potassium Phosphate injectable preparation manufactured for electrolyte replacement in hospital pharmacy settings.
  • Customer Portal Ordering Service Online ordering and account management platform allowing providers to browse the full SCA catalog, place orders, pay invoices, and track shipments in real time.
  • Buy and Ship Now Service Expedited order processing and direct shipment service offered through the SCA customer portal for urgent hospital pharmacy needs.
  • Pharmacy Reliability Program SCA's Pharmacy Reliability Program offers hospital pharmacies a stable, contracted supply of ready-to-use compounded sterile preparations, including extended BUD dating on 69+ products to reduce drug waste.

Quantifiable outcome

  • Buy & Ship Now orders ship within next business day for orders placed from available inventory
  • +3 more outcomes

Companies that use SCA Pharmaceuticals

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles1 record

SCA Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature9 records

SCA Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • MedigicoreChannel Partner/ Reseller/ Distributor · 26 May 2026Strategic partnership expansion providing direct access to controlled substances (CII products) through Medigi platform. Platform integration enables existing Medigi users to seamlessly add SCA Pharma products without retraining on new software systems.
  • MedigicoreChannel Partner/ Reseller/ Distributor · 10 September 2025SCA Pharma expanded distribution of core pharmaceutical products to Medigi digital procurement platform, providing healthcare facilities with additional purchasing options. Medigi integration enables streamlined ordering through existing hospital procurement systems with full product portfolio access including critical CII products.
  • VizientcoreChannel Partner/ Reseller/ Distributor · 1 November 2022Multi-year agreement awarded by Vizient for SCA Pharma's full range of 503B ready-to-use products. Vizient serves over 60% of U.S. health care organizations. Third-party 503B/cGMP assessment confirmed SCA facilities produce high-quality, safe, and efficacious products in compliance with 503B requirements.
  • Kit CheckcoreTechnology or Integration · 10 September 2020First 503B company to use Kit Check's embedded RFID tag on all products for automated medication tracking and safety verification. Enables medication intelligence through radio-frequency identification technology.
  • Bausch Advanced TechnologiesminorStrategic or Co-development Partner · 16 April 2020Partnership during COVID-19 to compound and distribute over 2,500 containers of alcohol-based hand sanitizer at no cost to first responders and front-line healthcare workers in Connecticut.

Scale indicators11 records

Recent moves9 records

Expansion highlights5 records

SCA Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • QuVa Pharma: QuVa is a 503B outsourcing facility providing sterile compounded admixtures and ready-to-use presentations to U.S. hospital pharmacies — the closest direct competitor to SCA in the same regulatory and product category.
  • Leiters Health: Leiters is a FDA-registered 503B outsourcing facility producing sterile admixtures, pre-filled syringes, and ophthalmic preparations for hospital and clinical customers — directly comparable in product format and end-market to SCA Pharma.
  • Olympia Pharmaceuticals: Olympia is a 503B-registered sterile outsourcing facility producing compounded sterile preparations for hospitals — comparable in regulatory standing, customer base, and product format to SCA.
  • Avella Specialty Pharmacy: Avella operates a 503B outsourcing facility producing sterile admixtures and prefilled syringes for hospital customers — overlaps directly with SCA's core product portfolio and hospital-segment focus.

Broad incumbents

  • B. Braun Medical (Central Admixture Pharmacy Services): B. Braun's Central Admixture Pharmacy Services (CAPS) is an established 503B sterile compounder serving hospitals nationally — competes directly with SCA but as part of a much larger medical products company.
  • Fagron: Fagron is a global leader in pharmaceutical compounding offering APIs, excipients, and compounding services — a broader industry incumbent with overlapping reach into sterile and non-sterile compounding adjacent to SCA's domain.
  • Pfizer CentreOne (Contract Manufacturing): Pfizer CentreOne provides contract sterile manufacturing and injectable supply to hospital and 503B-adjacent customers — a much larger incumbent with overlapping capacity and quality standards relevant to SCA's hospital customer base.
  • Curia: Curia is a contract development and manufacturing organization with sterile injectable fill-finish capabilities serving pharma and hospital customers — comparable in regulatory depth and sterile manufacturing scale to SCA though broader in scope.

Emerging players

  • Stokes Healthcare: Stokes operates a 503B outsourcing facility focused on sterile preparations for hospitals and specialty pharmacies — an emerging player with meaningful product overlap but smaller national reach than SCA.
  • Wells Pharma: Wells Pharma operates a 503B-registered sterile compounding outsourcing facility with hospital customers — emerging peer with comparable regulatory profile and product set but more limited national penetration than SCA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

SCA Pharmaceuticals social profiles

Digital presence

SCA Pharmaceuticals compliance and trust

Trust signal

Compliance5 records

SCA Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SCA Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles5 records

SCA Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SCA Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SCA Pharmaceuticals

What does SCA Pharmaceuticals do?

SCA Pharmaceuticals is an FDA-registered 503B outsourcing facility that performs cGMP-compliant sterile compounding of ready-to-use medications for hospital and healthcare facility pharmacies. The company manufactures pre-filled syringes, sterile IV admixtures, and other injectable preparations across approximately 200 product NDCs spanning 15 therapeutic categories. Operations run from two state-of-the-art facilities totaling 120,000 sq. ft. in Little Rock, AR and Windsor, CT, with the company licensed in 49 states and Washington D.C.

Is SCA Pharmaceuticals a public or private company?

SCA Pharmaceuticals is a private company. It is classified as private equity controlled and is currently operating.

When was SCA Pharmaceuticals founded?

SCA Pharmaceuticals was founded in 2017. It employs 251 to 500 people.

Where is SCA Pharmaceuticals based?

SCA Pharmaceuticals is headquartered in Little Rock, United States, in the North America region.

How does SCA Pharmaceuticals make money?

Two revenue lines are on record. Sterile Compounding Product Sales are the primary driver. The others are distribution Platform Sales.

Who are SCA Pharmaceuticals's main competitors?

Direct peers on record are QuVa Pharma, Leiters Health, Olympia Pharmaceuticals and Avella Specialty Pharmacy. Broad incumbents are B. Braun Medical (Central Admixture Pharmacy Services), Fagron, Pfizer CentreOne (Contract Manufacturing) and Curia. Emerging players are Stokes Healthcare and Wells Pharma.

Does SCA Pharmaceuticals have an API?

No public API is recorded for SCA Pharmaceuticals.

What industry is SCA Pharmaceuticals in?

SCA Pharmaceuticals's product category is Sterile Compounded Pharmaceuticals. Its primary akta.pro industry code is HLAFALAE, Compounding Pharmacies (Sterile/Non-Sterile), with a secondary code of HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Hartford Business JournalPrivate equity firms buy growing compounding pharmacy with Windsor plantTwo private equity firms, Vistria Group and Excellere Partners, acquired all of SCA Pharmaceuticals, a compounding pharmacy with Windsor operations. The terms were not disclosed, but SCA CEO Milton Boyer said the partners will fast-track expansion and automation. No operational changes are planned.Hartford Business JournalWindsor pharmaceutical biz expands footprint by 40%SCA Pharmaceuticals expanded its Windsor manufacturing site by nearly 60,000 square feet, increasing its footprint by 40% to 148,585 square feet. The company, which opened the Rainbow Road facility in fall 2017, plans to employ 361 by 2021.PR NewswireSCA Pharmaceuticals Celebrates Grand Opening of 90,000 Square Foot Production FacilitySCA Pharmaceuticals celebrated the grand opening of its 90,000 ft2 manufacturing facility in Windsor, Connecticut on November 27, 2017, attended by Governor Dannel P. Malloy and U.S. Senator Richard Blumenthal. The new facility features state-of-the-art cGMP cleanrooms and GLP Quality Control Laboratories to meet FDA regulations, and joins the company's existing Little Rock, Arkansas location to serve East Coast hospitals and surgery centers. The company plans to add over 200 additional full-time positions at the Windsor facility over the next three years, growing its workforce to over 360 employees.PR NewswireSCA Pharmaceuticals Appoints Milton Boyer as Chief Executive OfficerSCA Pharmaceuticals announced the appointment of Milton Boyer as Chief Executive Officer, succeeding founder Dr. Gene Graves who retired on September 6, 2017. Boyer brings over 25 years of pharmaceutical industry experience, most recently serving as Senior Vice President of Drug Product Manufacturing at AMRI, and will also join the company's Board of Directors. Under his leadership, the company plans to open a new 90,000-square-foot sterile manufacturing facility in Windsor, Connecticut this fall, adding 360 jobs over four years.